ABSTRACT
Since the last months of 2019, SARS-CoV-2, commonly referred to as COVID-19, has impacted the global economy and health care industries. Previous studies on SARS-CoV-2 have shown that it can also affect household pets. Coronaviruses have long been associated with pets, and prophylaxis is provided through vaccination programs. Today, although the levels of those requiring intensive care and death rates are decreasing through the extensive vaccination program initiated for humans, there is still no effective treatment for humans or pets. SARS-CoV-2 can spread and infect animals through similar mechanisms to that of humans. Like other types of coronavirus, Feline Infectious Peritonitis (FIP)-like multi-organ failure can develop in pets with COVID-19. Until now, supportive treatment has been performed to prevent severe cases and improve the quality of life. Molnupiravir, approved for emergency use by the FDA, is a prodrug of ribonucleoside analog with a low incidence of adverse side effects. Studies have shown that Molnupiravir has a preservative effect by preventing SARS-CoV-2 viral replication. Therefore we propose that Molnupiravir may also be used as a protective agent for pets and thus prevent multiple organ failures. © 2022 by the authors.
ABSTRACT
With the ongoing pandemic declared by the World Health Organization,the number of hospitalizations and deaths caused by COVID-19 is increasing dramatically. As new variants of SARS-CoV-2 emerge, new combination therapies are needed to reduce the risk of COVID-19spreadduring this time of increased transmission risk. In this case, it is vitalto strengthen the immune system against highly inflammatory conditions such as the cytokine storm caused by COVID-19. This brief review highlights the benefits of taking melatonin and the new antiviral drug molnupiravir together in the treatment of COVID-19. Webelieve that this combination therapy against COVID-19 would be of great benefit and should be considered as an adjuvant therapy in the treatment of this disease. Copyright © 2023, Ibn Sina Trust. All rights reserved.
ABSTRACT
SARS-CoV-2 infection has led to COVID-19 outbreak worldwide. To date, a specific antiviral drug does not exist to treat the disease and control the virus. In this paper, we have explored the potential utility of alpha lipoic acid, an anti-inflammatory and antioxidant molecule, for treatment. Alpha lipoic acid exhibits strong antioxidant properties and modulates the immune system by regulating T cell activation making it a useful therapeutic candidate for cytokine storm triggering SARS-CoV-2 infection. In the present communication, we focused on the therapeutic potential of ALA with respect to its potential role on reducing the severity of symptoms and the adverse effects of other antiviral drugs used. We consider different mechanisms by which modulating ACE2 levels after virus replication and preventing cytokine storm and also focus on a new therapeutic venue that utilizes ALA.